We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Innovative cancer drugs are taking longer to get from clinical trials to EMA approval and availability for UK patients than more conventional treatments, the London-based Institute of Cancer Research (ICR) reported. Read More
A House subcommittee took up four bipartisan drug bills yesterday, including one — introduced in October — that would close a loophole in the FDA’s orphan drug program. Read More
The U.S. Deputy Attorney General has asked the House to vote by a Feb. 6 deadline to extend an emergency order that categorizes all fentanyl analogues as Schedule I drugs. Read More
The Association for Accessible Medicines (AAM) has asked a federal appeals court to suspend California’s pay-for-delay ban pending an appeal of a lower court’s ruling. Read More
In a first for the Department of Justice, an electronic health records software vendor has agreed to a $145 million settlement over allegations that it created a kickback scheme aimed at prescribing opioids. Read More
The FDA unveiled seven guidances yesterday that clarify the agency’s policies for sponsors of gene therapy products for specific disease areas. Read More
New York Attorney General Letitia James and the Federal Trade Commission has filed suit against Martin Shkreli and Vyera Pharmaceuticals for an “elaborate anticompetitive scheme” to monopolize toxoplasmosis treatment Daraprim (pyrimethamine), the government officials announced yesterday. Read More
The plaintiffs are seeking an injunction, arguing that the alleged behavior will “continue unchecked” and “put an unbearable strain on third-party payers.” Read More